Page 23 of 36
Molecular Pharmaceutics
1
2
3
4
5
6
35.
Adas, F.; Salaun, J. P.; Berthou, F.; Picart, D.; Simon, B.; Amet, Y. Requirement for omega and
(omega;-1)-hydroxylations of fatty acids by human cytochromes P450 2E1 and 4A11. J Lipid Res 1999,
40, (11), 1990-7.
36.
Wang, M. H.; Stec, D. E.; Balazy, M.; Mastyugin, V.; Yang, C. S.; Roman, R. J.; Schwartzman, M. L.
7
8
Cloning, sequencing, and cDNA-directed expression of the rat renal CYP4A2: arachidonic acid omega-
9
hydroxylation and 11,12-epoxidation by CYP4A2 protein. Arch Biochem Biophys 1996, 336, (2), 240-50.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
37.
Lee, E.; Kariya, K. Propylthiouracil, a selective inhibitor of NADH-cytochrome b5 reductase. FEBS
Lett 1986, 209, (1), 49-51.
38.
S.; Totah, R. A. Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
Drug Metab Dispos 2012, 40, (5), 943-51.
39.
cytochrome P450 2B6. J Clin Pharmacol 2006, 46, (12), 1426-38.
40. Brown, V. A.; Patel, K. R.; Viskaduraki, M.; Crowell, J. A.; Perloff, M.; Booth, T. D.; Vasilinin, G.;
Sen, A.; Schinas, A. M.; Piccirilli, G.; Brown, K.; Steward, W. P.; Gescher, A. J.; Brenner, D. E. Repeat dose
study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics,
and effect on the insulin-like growth factor axis. Cancer Res 2010, 70, (22), 9003-11.
Lee, C. A.; Jones, J. P., 3rd; Katayama, J.; Kaspera, R.; Jiang, Y.; Freiwald, S.; Smith, E.; Walker, G.
Walsky, R. L.; Astuccio, A. V.; Obach, R. S. Evaluation of 227 drugs for in vitro inhibition of
41.
Sale, S.; Verschoyle, R. D.; Boocock, D.; Jones, D. J.; Wilsher, N.; Ruparelia, K. C.; Potter, G. A.;
Farmer, P. B.; Steward, W. P.; Gescher, A. J. Pharmacokinetics in mice and growth-inhibitory properties
of the putative cancer chemopreventive agent resveratrol and the synthetic analogue trans 3,4,5,4'-
tetramethoxystilbene. Br J Cancer 2004, 90, (3), 736-44.
42.
Chemotherapy 1993, 39, (1), 6-12.
43. Berl, T.; Wilner, K. D.; Gardner, M.; Hansen, R. A.; Farmer, B.; Baris, B. A.; Henrich, W. L.
Pharmacokinetics of fluconazole in renal failure. J Am Soc Nephrol 1995, 6, (2), 242-7.
44. Felton, T.; Troke, P. F.; Hope, W. W. Tissue penetration of antifungal agents. Clin Microbiol Rev
2014, 27, (1), 68-88.
Ripa, S.; Ferrante, L.; Prenna, M. Pharmacokinetics of fluconazole in normal volunteers.
45.
Kalsotra, A.; Turman, C. M.; Kikuta, Y.; Strobel, H. W. Expression and characterization of human
cytochrome P450 4F11: Putative role in the metabolism of therapeutic drugs and eicosanoids.
Toxicology and applied pharmacology 2004, 199, (3), 295-304.
46.
understanding drug and xenobiotic metabolism. The Journal of biological chemistry 2013, 288, (18),
12932-43.
47.
biochemical perspective. Expert opinion on drug metabolism & toxicology 2008, 4, (8), 1053-64.
48. Williams, P. A.; Cosme, J.; Ward, A.; Angove, H. C.; Matak Vinkovic, D.; Jhoti, H. Crystal structure
of human cytochrome P450 2C9 with bound warfarin. Nature 2003, 424, (6947), 464-8.
49. Reynald, R. L.; Sansen, S.; Stout, C. D.; Johnson, E. F. Structural characterization of human
cytochrome P450 2C19: active site differences between P450s 2C8, 2C9, and 2C19. The Journal of
biological chemistry 2012, 287, (53), 44581-91.
50.
Walsh, A. A.; Szklarz, G. D.; Scott, E. E. Human cytochrome P450 1A1 structure and utility in
Miller, G. P. Advances in the interpretation and prediction of CYP2E1 metabolism from a
Schoch, G. A.; Yano, J. K.; Sansen, S.; Dansette, P. M.; Stout, C. D.; Johnson, E. F. Determinants of
cytochrome P450 2C8 substrate binding: structures of complexes with montelukast, troglitazone,
felodipine, and 9-cis-retinoic acid. The Journal of biological chemistry 2008, 283, (25), 17227-37.
51.
Freiwald, S.; Zientek, M.; Totah, R. A. Identification of novel substrates for human cytochrome P450 2J2.
Drug metabolism and disposition: the biological fate of chemicals 2010, 38, (2), 347-56.
Lee, C. A.; Neul, D.; Clouser-Roche, A.; Dalvie, D.; Wester, M. R.; Jiang, Y.; Jones, J. P., 3rd;
24
ACS Paragon Plus Environment